Additionally, Sahin and collaborators (2020) conducted phase I trials testing the melanoma liposomal RNA vaccine (BNT111) against four non-mutated antigens, including TPTE, Tyrosinase, melanoma-associated antigen A3 (MAGE-A3), and New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1). The gene discussed is MAGEA3; the disease is esophageal squamous cell carcinoma.